135 related articles for article (PubMed ID: 11392545)
1. A new structural class of selective and non-covalent inhibitors of the chymotrypsin-like activity of the 20S proteasome.
García-Echeverría C; Imbach P; France D; Fürst P; Lang M; Noorani AM; Scholz D; Zimmermann J; Furet P
Bioorg Med Chem Lett; 2001 May; 11(10):1317-9. PubMed ID: 11392545
[TBL] [Abstract][Full Text] [Related]
2. Modeling of the binding mode of a non-covalent inhibitor of the 20S proteasome. Application to structure-based analogue design.
Furet P; Imbach P; Fürst P; Lang M; Noorani M; Zimmermann J; García-Echeverria C
Bioorg Med Chem Lett; 2001 May; 11(10):1321-4. PubMed ID: 11392546
[TBL] [Abstract][Full Text] [Related]
3. Structure-based optimisation of 2-aminobenzylstatine derivatives: potent and selective inhibitors of the chymotrypsin-like activity of the human 20S proteasome.
Furet P; Imbach P; Fuerst P; Lang M; Noorani M; Zimmermann J; García-Echeverría C
Bioorg Med Chem Lett; 2002 May; 12(10):1331-4. PubMed ID: 11992770
[TBL] [Abstract][Full Text] [Related]
4. Structure-based design of derivatives of tyropeptin A as the potent and selective inhibitors of mammalian 20S proteasome.
Momose I; Umezawa Y; Hirosawa S; Iinuma H; Ikeda D
Bioorg Med Chem Lett; 2005 Apr; 15(7):1867-71. PubMed ID: 15780623
[TBL] [Abstract][Full Text] [Related]
5. Human platelet 20S proteasome: inhibition of its chymotrypsin-like activity and identification of the proteasome activator PA28. A preliminary report.
Ostrowska H; Ostrowska JK; Worowski K; Radziwon P
Platelets; 2003 May; 14(3):151-7. PubMed ID: 12850839
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibitors; synthesis and activity of arecoline oxide tripeptide derivatives.
Marastoni M; McDonald J; Baldisserotto A; Canella A; De Risi C; Pollini GP; Tomatis R
Bioorg Med Chem Lett; 2004 Apr; 14(8):1965-8. PubMed ID: 15050638
[TBL] [Abstract][Full Text] [Related]
7. Entry into a new class of potent proteasome inhibitors having high antiproliferative activity by structure-based design.
Furet P; Imbach P; Noorani M; Koeppler J; Laumen K; Lang M; Guagnano V; Fuerst P; Roesel J; Zimmermann J; García-Echeverría C
J Med Chem; 2004 Sep; 47(20):4810-3. PubMed ID: 15369383
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and activity of tyropeptin A derivatives as potent and selective inhibitors of mammalian 20S proteasome.
Momose I; Umezawa Y; Hirosawa S; Iijima M; Iinuma H; Ikeda D
Biosci Biotechnol Biochem; 2005 Sep; 69(9):1733-42. PubMed ID: 16195592
[TBL] [Abstract][Full Text] [Related]
9. Arecoline tripeptide inhibitors of proteasome.
Marastoni M; Baldisserotto A; Canella A; Gavioli R; Risi CD; Pollini GP; Tomatis R
J Med Chem; 2004 Mar; 47(6):1587-90. PubMed ID: 14998343
[TBL] [Abstract][Full Text] [Related]
10. Modulation of the chymotrypsin-like activity of the 20S proteasome by intracellular redox status: effects of glutathione peroxidase-1 overexpression and antioxidant drugs.
Kretz-Remy C; Arrigo AP
Biol Chem; 2003 Apr; 384(4):589-95. PubMed ID: 12751788
[TBL] [Abstract][Full Text] [Related]
11. Cathepsin A and chymotrypsin-like activity of the proteasome in human blood platelets.
Ostrowska H; Wójcik C; Worowski K
Folia Histochem Cytobiol; 1999; 37(2):153-4. PubMed ID: 10353004
[No Abstract] [Full Text] [Related]
12. Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology.
Sin N; Kim KB; Elofsson M; Meng L; Auth H; Kwok BH; Crews CM
Bioorg Med Chem Lett; 1999 Aug; 9(15):2283-8. PubMed ID: 10465562
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in the identification and development of 20S proteasome inhibitors.
García-Echeverría C
Mini Rev Med Chem; 2002 Jun; 2(3):247-59. PubMed ID: 12370066
[TBL] [Abstract][Full Text] [Related]
14. Specific inhibition of the chymotrypsin-like activity of the proteasome induces a bipolar morphology in neuroblastoma cells.
Fenteany G; Schreiber SL
Chem Biol; 1996 Nov; 3(11):905-12. PubMed ID: 8939705
[TBL] [Abstract][Full Text] [Related]
15. Kinetic studies of the branched chain amino acid preferring peptidase activity of the 20S proteasome: development of a continuous assay and inhibition by tripeptide aldehydes and clasto-lactacystin beta-lactone.
McCormack TA; Cruikshank AA; Grenier L; Melandri FD; Nunes SL; Plamondon L; Stein RL; Dick LR
Biochemistry; 1998 May; 37(21):7792-800. PubMed ID: 9601040
[TBL] [Abstract][Full Text] [Related]
16. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity.
Meng L; Mohan R; Kwok BH; Elofsson M; Sin N; Crews CM
Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10403-8. PubMed ID: 10468620
[TBL] [Abstract][Full Text] [Related]
17. Structural investigation of proteasome inhibition.
Ditzel L; Stock D; Löwe J
Biol Chem; 1997; 378(3-4):239-47. PubMed ID: 9165077
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibition of the chymotrypsin-like activity of the 20S proteasome by 5-methoxy-1-indanone dipeptide benzamides.
Lum RT; Nelson MG; Joly A; Horsma AG; Lee G; Meyer SM; Wick MM; Schow SR
Bioorg Med Chem Lett; 1998 Feb; 8(3):209-14. PubMed ID: 9871656
[TBL] [Abstract][Full Text] [Related]
19. Probing structural determinants distal to the site of hydrolysis that control substrate specificity of the 20S proteasome.
Groll M; Nazif T; Huber R; Bogyo M
Chem Biol; 2002 May; 9(5):655-62. PubMed ID: 12031672
[TBL] [Abstract][Full Text] [Related]
20. Modulation of the PA28alpha-20S proteasome interaction by a peptidyl alcohol.
Wilk S; Chen WE; Magnusson RP
Arch Biochem Biophys; 1999 Feb; 362(2):283-90. PubMed ID: 9989937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
